MedTrace Logo

Vitamin E for NASH Treatment in HIV Infected Individuals

NCT03669133 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2023-07-25

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to see how taking Vitamin E daily affects fatty liver in persons living with HIV. Subjects will have both HIV and a fatty liver and the purpose of the study is to learn if underlying liver condition (fatty liver) gets better, worse, or stays the same from taking Vitamin E.

Conditions

  • NAFLD
  • NASH - Nonalcoholic Steatohepatitis
  • HIV Infections

Interventions

DRUG

Vitamin E

Vitamin E 800 IU/daily

DRUG

Placebo

Matching placebo daily

Sponsors & Collaborators

  • Indiana University School of Medicine

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-01
Primary Completion
2021-03-08
Completion
2021-03-08
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03669133 on ClinicalTrials.gov